Guardant Health (NASDAQ:GH) Insider Chris Freeman Sells 24,406 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) insider Chris Freeman sold 24,406 shares of the stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $118.67, for a total value of $2,896,260.02. Following the sale, the insider owned 60,034 shares in the company, valued at approximately $7,124,234.78. This represents a 28.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Guardant Health Trading Up 0.8%

Shares of GH opened at $119.85 on Wednesday. The business’s fifty day simple moving average is $92.53 and its two-hundred day simple moving average is $99.26. Guardant Health, Inc. has a 12 month low of $37.73 and a 12 month high of $121.01. The company has a market cap of $15.89 billion, a price-to-earnings ratio of -35.35 and a beta of 1.48.

Hedge Funds Weigh In On Guardant Health

A number of institutional investors and hedge funds have recently modified their holdings of the company. BankChampaign National Association bought a new position in Guardant Health in the 1st quarter worth $809,000. Western Wealth Management LLC bought a new position in Guardant Health in the 1st quarter worth $125,000. Hamilton Wealth LLC raised its holdings in Guardant Health by 103.0% in the 1st quarter. Hamilton Wealth LLC now owns 76,700 shares of the company’s stock worth $7,085,000 after purchasing an additional 38,916 shares during the period. Edgestream Partners L.P. raised its holdings in Guardant Health by 321.6% in the 1st quarter. Edgestream Partners L.P. now owns 32,257 shares of the company’s stock worth $2,980,000 after purchasing an additional 24,606 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in Guardant Health by 19.4% in the 1st quarter. Janus Henderson Group PLC now owns 140,345 shares of the company’s stock worth $12,960,000 after purchasing an additional 22,844 shares during the period. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

GH has been the topic of a number of research reports. Wells Fargo & Company raised their price target on Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, February 20th. Barclays raised their price target on Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Stifel Nicolaus raised their price target on Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Robert W. Baird initiated coverage on Guardant Health in a research note on Tuesday, February 17th. They issued an “outperform” rating and a $120.00 price target on the stock. Finally, Raymond James Financial restated an “outperform” rating and issued a $129.00 price target on shares of Guardant Health in a research note on Monday, February 23rd. Nineteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $129.53.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.